Search Videos and More
News
Kornelia Polyak Wins Prestigious American Cancer Society Award
Kornelia Polyak, MD, PhD, a breast cancer researcher at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School is the recipient of the American Cancer Society’s prestigious Research Professor Award.
Document
Adjuvant Olaparib for BRCA1/2 Variant Carriers
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on May 6, May 20, June 1, and August 5, 2022 to discuss recommendations for the use of adjuvant olaparib for high-risk, breast cancer in BRCA1/2 carriers.Symposium Highlights 75 Years of Dana-Farber Science
Video
Welcome Session | 2022-2023 EMBRACE MBC Virtual Forum Series
Nancy Lin, MD; Sara Tolaney, MD, MPH; and patient advocate Lianne Kraemer discuss new developments and promising areas of research in metastatic breast cancer at Dana-Farber and beyond.
Video
Research Update for HER2-Positive MBC | 2022-2023 EMBRACE MBC Virtual Forum Series
Philip Poorvu, MD; Adrienne Waks, MD; and Christine Agius, NP, discuss advances in research and treatment for patients with HER2-positive metastatic breast cancer.
Video
Research Update for ER-Positive MBC | 2022-2023 EMBRACE MBC Virtual Forum Series
Filipa Lynce, MD; Nikhil Wagle, MD; and Lindsay Shaw, AOCNP, ACHPN, discuss advances in research and treatment for patients with ER-positive metastatic breast cancer.
Document
Reflex Testing of OncotypeDX for Early Stage Breast Cancer
The Breast Oncology Center held multidisciplinary meetings to discuss recommendations for updated criteria for reflex testing of OncotypeDX in patients with resected, hormone receptor positive, HER-2 negative, early breast cancer.
Video
Best Practices for Rectal Cancer
Dana-Farber’s Young-Onset Colorectal Cancer Center's Gut Instincts series continued on Monday, September 26 with an educational workshop on Best Practices for Rectal Cancer.
News
Advancing New Treatments for Uncommon Cancer Subtypes
The biology of rare cancers is poorly understood in part because the tumors are uncommon, which makes them challenging to study. Clinical trials examining rare cancers are difficult.
Symposium
2022 ESMO Congress Research Highlights
In the following videos, faculty from Dana-Farber Cancer Institute review research highlights from the ESMO Congress 2022 held in Paris, France, September 9-13, 2022.
News
For Older Patients with Blood Cancer Taking Multiple Medications, New Tool Links Use of Certain Medications to Risk of Frailty
A new tool developed by researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital outperforms conventional methods for predicting whether certain medications are likely to lead to frailty in older patients with blood cancers who are taking multiple medications, a study being published online today indicates.
News
In Memoriam: Arthur T. Skarin, MD, Physician-Scientist Instrumental in Building Dana-Farber’s Adult Oncology Program
The Dana-Farber community mourns the passing of Arthur T. Skarin, MD, of Needham, Massachusetts.